J Clin Endocrinol Metab

Combination therapy boosts height in boys with idiopathic short stature

May 7, 2025

Study details: This study evaluated the efficacy and safety of combining third-generation aromatase inhibitors (AIs) with recombinant human growth hormone (rhGH) or gonadotrophin releasing hormone analogue (GnRHa) in adolescent boys with idiopathic short stature (ISS) and advanced bone age (≥13 years). Conducted at Tongji Hospital, Huazhong University of Science and Technology, the study included 96 participants divided into three groups: letrozole + rhGH, anastrozole + rhGH, and GnRHa + rhGH. Follow-up was conducted every three months until adult height was reached.

Results: The anastrozole + rhGH group showed the most significant increase in adult height, with a standard deviation score of 0.81 ± 0.34, compared with 0.60 ± 0.28 for letrozole and 0.48 ± 0.17 for GnRHa. Combination therapy was effective in increasing adult height, with anastrozole demonstrating superior results and fewer adverse reactions.

Clinical impact: For adolescent males with ISS, combining AIs with rhGH significantly enhances adult height potential. Anastrozole, in particular, offers a promising treatment option with minimal adverse effects, potentially improving long-term growth outcomes for this patient population.

Source:

Cui Y, et al. (2025, April 26). J Clin Endocrinol Metab. The combination of Aromatase inhibitors and growth hormone treatment for idiopathic short stature in male adolescents. https://pubmed.ncbi.nlm.nih.gov/40326775/